Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0IGMTO
ADC Name	Dualtargeting lidamycin ADC
Synonyms	Dualtargeting ligandbased LDM; DTLL Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Pancreatic ductal adenocarcinoma [ICD11:2C10] Investigative
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Lidamycin		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 56.63	%	Pancreatic cancer PDX model (PDX: PA1338)

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.63%±9.71%	Positive EGFR expression (EGFR+++/++)
Method Description	PDX mice were administrated vehicle or DTLL at the LDMequivalent dose of 0.1 mg/kg once a week for 3 wk. Tumor volumes were measured after animals were sacrificed on Days 24 and 39, respectively. DTLL was administered via tail vein injection once a week for three weeks.
In Vivo Model	Pancreatic cancer PDX model (PDX: PA1338)

References

Ref 1	Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. Cancer Med. 2019 Feb;8(2):643-655. doi: 10.1002/cam4.1974. Epub 2019 Jan 25.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.